Kyle Piskel Sells 18,672 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 18,672 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $245,910.24. Following the sale, the chief financial officer owned 259,840 shares of the company’s stock, valued at approximately $3,422,092.80. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kyle Piskel also recently made the following trade(s):

• On Wednesday, February 4th, Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.46, for a total transaction of $39,596.70.
• On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00.

Adaptive Biotechnologies Trading Up 5.8%

Shares of NASDAQ ADPT opened at $13.17 on Friday. The firm has a 50 day moving average of $16.55 and a 200 day moving average of $15.87. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12-month low of $6.68 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm’s revenue was up 51.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.23) earnings per share. Sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on ADPT. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Guggenheim lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADPT. Ameriprise Financial Inc. grew its holdings in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $65,942,000. Geode Capital Management LLC boosted its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after acquiring an additional 110,825 shares during the last quarter. Finally, State Street Corp grew its stake in Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.